When will Compass Pathways submit a NDA for COMP360 psilocybin?
1.0 pts (24h)Health & MedicineOne-OffScienceBusiness & Corporate21d
KalshiCheck availabilityKYC required2% feeVerified resolution dataFairly calibratedCurrent implied probability
before April 2027 83%Leader of 6 outcomes
Market quality
40 / 100
Low quality24h Volume
$500
Liquidity
$10.1K
Medium liquiditySpread
28.0 pt
Wide spreadMarket data
Updated 6 minutes ago
Mar 24, 26, 2:00 PM UTCOct 1, 26, 2:00 PM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
When will the FDA approve Compass Pathways' COMP360 Psilocybin?
KalshiWhen will Beam Therapeutics submit a BLA for Risto-cel?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill psilocybin remain Schedule I through the end of 2027?
Manifold MarketsWill the FDA approve a psilocybin treatment during 2026?
FutuurWhich fast food chain in the USA will offer a lab-grown / cultivated meat product first?
Manifold MarketsRules
If COMPASS Pathways plc submits a NDA for COMP360 psilocybin to the FDA before Sep 1, 2026, then the market resolves to Yes.
- If COMPASS Pathways plc submits a NDA for COMP360 psilocybin to the FDA before Oct 1, 2026, then the market resolves to Yes.
- If COMPASS Pathways plc submits a NDA for COMP360 psilocybin to the FDA before Nov 1, 2026, then the market resolves to Yes.
- If COMPASS Pathways plc submits a NDA for COMP360 psilocybin to the FDA before Dec 1, 2026, then the market resolves to Yes.
- If COMPASS Pathways plc submits a NDA for COMP360 psilocybin to the FDA before Jan 1, 2027, then the market resolves to Yes.
- If COMPASS Pathways plc submits a NDA for COMP360 psilocybin to the FDA before Apr 1, 2027, then the market resolves to Yes.
Open markets
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Total Vol
- $18.1M
- 24h Vol
- $23.7K
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Total Vol
- $1.1M
- 24h Vol
- $4.9K
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 more outcomes
- Total Vol
- $3K
- 24h Vol
- $3K
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k+0.1pt100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 more outcomes
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000+2.0pt61%
+2 more outcomes
- Total Vol
- $1M
- 24h Vol
- $2K
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Total Vol
- $712K
- 24h Vol
- $1.3K
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Which countries will report an Ebola disease case before October?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Heidi Overton confirmed as FDA Commissioner by which date?
- Will the FDA approve retatrutide?
- Ebola pandemic in 2026?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- Measles cases in U.S. by September 30?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- FDA approves Retatrutide this year?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
Frequently asked questions
- What are the current odds for When will Compass Pathways submit a NDA for COMP360 psilocybin??
- Kalshi prices before April 2027 at 83% as of September 10, 2026.
- When does When will Compass Pathways submit a NDA for COMP360 psilocybin? resolve?
- When will Compass Pathways submit a NDA for COMP360 psilocybin? is scheduled to resolve on October 1, 2026.
- How is When will Compass Pathways submit a NDA for COMP360 psilocybin? settled?
- Kalshi settles this market as follows: If COMPASS Pathways plc submits a NDA for COMP360 psilocybin to the FDA before Sep 1, 2026, then the market resolves to Yes.